Skip to main content
TipRanks
Go Ultimate75% OFF

Interpace Diagnostics Group (IDXG) AI Stock Analysis

413 Followers
IDXG

Interpace Diagnostics Group

(Other OTC:IDXG)

Select Model
Rating:62Neutral
Price Target:$6.00â–²(0.00% Upside)
Action:reiterated
Date:09/28/26

The score is primarily supported by improved financial strength (profitability turnaround, positive equity, and low leverage). It is held back by weakening business momentum (declining revenue and softer cash conversion in TTM) and bearish technicals (price below key moving averages with negative MACD). Valuation looks extremely low but is tempered by uncertainty around earnings sustainability; corporate actions related to an uplisting are a modest positive with some signaling risk.

Positive Factors
Profitability TurnaroundThe shift from sizable earlier losses to sustained profitability through 2023–2025 indicates materially improved operating performance. If maintained, positive operating income can strengthen internal funding capacity, support investment in diagnostic offerings, and reduce reliance on external capital over the next several quarters.
Negative Factors
Revenue DeclineFalling revenue weakens the underlying growth profile of the diagnostics business and may limit operating leverage, reinvestment capacity, and future earnings expansion. Continued contraction could offset recent profitability gains by reducing test volume or the revenue base supporting fixed operating costs.

Interpace Diagnostics Group (IDXG) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%175%IDXG+38.73%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$36.59M
Dividend Yield
―
Average Volume (3M)
2,748
Price to Earnings (P/E)
0.2
Beta (1Y)
1.36
Revenue Growth
-20.48%
EPS Growth
537.47%
Country
US
Employees
102
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Interpace Diagnostics Group Business Overview & Revenue Model

Company Description

Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic...

How the Company Makes Money

IDXG makes money primarily by providing clinical diagnostic testing services and collecting reimbursement for those tests. The core revenue model is fee-for-service: physicians (and other healthcare providers) order the company’s tests for appropriat...

Interpace Diagnostics Group Financial Statement Overview

Summary

Financials show a meaningful turnaround: strong profitability versus 2021–2022 losses, positive equity, and very low debt in 2025 and TTM. Offsetting this, revenue is declining in 2025 and TTM, and cash flow momentum weakened in TTM with operating cash flow falling below net income, raising questions about durability of earnings quality.

Income Statement

70Positive

Balance Sheet

78Positive

Cash Flow

66Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Mar 2022
Income Statement
Total Revenue36.14M38.73M46.93M40.21M31.84M41.31M
Gross Profit23.04M24.13M29.93M23.90M18.23M17.95M
EBITDA4.83M4.76M8.36M4.41M-2.27M-1.33M
Net Income24.45M24.57M6.70M802.00K-5.87M-14.75M
Balance Sheet
Total Assets34.55M33.84M14.79M13.02M15.98M38.43M
Cash, Cash Equivalents and Short-Term Investments2.69M2.50M1.46M3.50M4.83M3.31M
Total Debt974.00K1.18M5.86M11.19M16.09M10.72M
Total Liabilities11.30M11.47M17.01M28.16M79.05M80.84M
Stockholders Equity23.24M22.36M-2.22M-15.14M-63.07M-42.42M
Cash Flow
Free Cash Flow4.10M5.47M3.77M3.32M-8.01M-9.07M
Operating Cash Flow4.46M5.83M4.65M3.79M-7.69M-8.72M
Investing Cash Flow-353.00K-356.00K-876.00K-87.00K6.21M-315.00K
Financing Cash Flow-1.92M-4.43M-5.81M-5.03M3.00M8.98M

Interpace Diagnostics Group Technical Analysis

Technical Analysis SentimentNegative
Last Price6.00

Price Trends

50DMA6.09Negative
100DMA6.94Negative
200DMA8.06Negative

Market Momentum

MACD0.07Negative
RSI49.03Neutral
STOCH28.66Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXG, the sentiment is Negative. The current price of 6.00 is above the 20-day moving average (MA) of 5.95, below the 50-day MA of 6.09, and below the 200-day MA of 8.06, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 49.03 is Neutral, neither overbought nor oversold. The STOCH value of 28.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDXG.

Interpace Diagnostics Group Risk Analysis

Interpace Diagnostics Group disclosed 63 risk factors in its most recent earnings report. Interpace Diagnostics Group reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our existing clinical utility studies may be outdated and may not reflect current medical practice, which could adversely affect acceptance of our products and services.Q4, 2025
2.Evolving regulation of algorithm-based and bioinformatics tools could increase compliance obligations.Q4, 2025
3.We reached a determination to restate certain of our previously issued consolidated financial statements as a result of the identification of errors in previously issued consolidated financial statements, which resulted in unanticipated costs and may affect investor confidence and raise reputational issues.Q4, 2024

Interpace Diagnostics Group Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IDXG against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
VCYTVCYT70Outperform$1.94B15.179.27%―17.50%311.25%
NEONEO65Neutral$1.99B-62.87-3.97%―11.08%71.76%
CSTLCSTL63Neutral$1.01B-42.38-4.89%―9.78%-81.20%
IDXGIDXG62Neutral$36.59M0.2393.92%―-20.48%537.47%
MYGNMYGN55Neutral$534.29M-4.11-40.40%―-2.63%68.56%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GHGH44Neutral$19.49B-39.45249.03%―41.69%-14.59%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%IDXGMYGNVCYTNEOGHCSTLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IDXG and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IDXGInterpace Diagnostics Group Inc.6.001.7039.53%
MYGNMyriad Genetics5.54-0.90-13.98%
VCYTVeracyte Inc24.23-15.70-39.32%
NEONeoGenomics Inc.15.254.9748.35%
GHGuardant Health143.2843.7343.93%
CSTLCastle Biosciences32.98-1.67-4.82%

Interpace Diagnostics Group Corporate Events

Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split

Interpace Diagnostics Executes Reverse Split to Support Nasdaq Uplisting

Positive
Aug 27, 2026

At the August 20, 2026 annual meeting, Interpace Biosciences’ stockholders approved giving the board discretion to implement a reverse stock split between 1-for-2 and 1-for-10, and the board subsequently set the ratio at 1-for-5. Following the filing...

Business Operations and StrategyShareholder MeetingsStock Split

Interpace Diagnostics Shareholders Approve Governance and Equity Plans

Positive
Aug 21, 2026

At its August 20, 2026 annual meeting, Interpace Diagnostics Group shareholders approved an amended and restated certificate of incorporation and granted the board authority to implement a reverse stock split within a one-for-two to one-for-ten range...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 27, 2026